Industry Type: ALL Conventional Industry High-Tech Industry Service Industry Emerging Industry    Title:  

Food Biotechnology Industry 2025-Sep Doc　#42893 Industry Report (condensed version) US$300 The domestic industry is projected to return to a growth trajectory in the fourth quarter of 2025. Nevertheless, a potential short-term reduction in import tariffs on nutritional supplements could exert downward pressure on the revenue of local probiotic manufacturers. Assessing the Impact of the U.S. One Big Beautiful Bill (OBBB) on Taiwan’s Green Energy Industry 2025-Sep Doc　#42712 Industry Report (condensed version) US$300 The legislation also raises entry barriers for Chinese companies seeking access to the U.S. market. With Chinese overseas expansion constrained and the Chinese government restricting exports of key technologies, such as battery cathode materials, Taiwanese companies that establish reliable U.S. partnerships and robust local supply chains are well-positioned to capture business opportunities previously dominated by Chinese firms. Biopharmaceutical Manufacturing 2025-May Doc　#42255 Industry Report (condensed version) US$300 The launch of certain Taiwanese-developed biological and biosimilar drugs in the U.S. market has faced delays, primarily due to reduced staffing at pharmaceutical regulatory agencies under the Trump administration. This, combined with persistent weakness in China's self-funded vaccine market, has intensified pressure on Taiwanese manufacturers seeking to expand their U.S. market presence. Nevertheless, overseas sales are expected to remain supported by the continued performance of domestically developed, special-indication biological drugs—such as PharmaEssentia Corporation’s Ropeg and Tanvex BioPharma Inc’s Nypozi—which have already entered international markets. Additionally, Taiwan’s public vaccine procurement volume is projected to rise in 2025 compared to 2024, further supporting domestic demand. Biotechnology Services 2025-Jan Doc　#41539 Industry Report (condensed version) US$300 Government-backed initiatives to support the biomedical sector, coupled with enhanced regulatory compliance and the return of domestic medical capacity to pre-pandemic levels, are poised to optimize the operations of local clinical and preclinical CRO and CDMO firms. These favorable conditions are expected to propel continued growth in Taiwan's biotechnology services industry in 2025. Agricultural Biotechnology lndustry 2024-Nov Doc　#41173 Industry Report (condensed version) US$300 The agricultural biotechnology industry’s output value is expected to remain on a downward trend in Q4 2024, though the rate of decline is anticipated to moderate. Wind Power 2024-Jun Doc　#40498 Industry Report (condensed version) US$300 The annual growth rate of the industry's production value in 2024 is expected to be smaller than in 2023. However, the overall prosperity and development of the industry will continue to maintain a positive trend. China's Traditional Chinese Medicine Industry-Brief Report 2024-Jun Doc　#C_7043 Industry Report (condensed version) US$350 With the growing acceptance of specialty Chinese herbal medicines and their products both domestically and internationally, it is expected that China's traditional Chinese medicine manufacturing industry will resume growth in the second half of 2024. Traditional Chinese Medicine 2024-Apr Doc　#40060 Industry Report (condensed version) US$300 Given the elevated starting point from the preceding period, the industry landscape is poised to exhibit a degree of stagnation throughout the initial half of 2024. Biotechnology Services 2024-Mar Doc　#39854 Industry Report (condensed version) US$300 In 2024, Taiwan's biotechnology service industry is poised to navigate through a landscape marked by both challenges and opportunities. Fierce competition from established players in South Korea and China, delays in the clinical trial process for new drugs both domestically and abroad, and the high costs associated with obtaining key raw materials for manufacturing, suggest the industry's growth momentum may experience pressure. Food Biotechnology Industry 2024-Mar Doc　#39780 Industry Report (condensed version) US$300 The industry is poised to rebound and return to a trajectory of stable growth in the first half of 2024.  First  Previous  Next  Last  In  1  /  8  Page  (Find  74  records)

Copyright (c) 2018 All Rights Reserved by
Taiwan Institute of Economic Research
Taiwan Industry Economics Services
Address: 4Fl., 16-8, Tehui St., Taipei, Taiwan
TEL: 886-2-25865000 ext469; FAX: 886-2-25935543